Drug – bio-affecting and body treating compositions – Enzyme or coenzyme containing – Hydrolases
Patent
1992-08-07
1995-10-10
Draper, Garnette D.
Drug, bio-affecting and body treating compositions
Enzyme or coenzyme containing
Hydrolases
424 9464, 514 8, 530386, 435 696, A61K 3836, A61K 3849
Patent
active
054569095
ABSTRACT:
The present invention relates to novel glycoforms and preparations of the soluble complement receptor type 1 (sCR1), and their uses in the therapy of complement mediated diseases and disorders involving inflammation and inappropriate complement activation and in thrombotic or shock state conditions. The invention provides novel glycoforms and methods for producing, detecting, enriching and purifying such glycoforms. The invention further provides methods of specifically producing a glycoform by recombinant or chemical means. Preferred embodiments of the invention include sialylated glycoforms and glycoforms with a pI.ltoreq.5.1 determined by chromatofocusing or with a sialic acid to mannose molar ratio of >0.25. The glycoforms may be formulated alone in therapeutic compositions or in combination with thrombolytic agents.
REFERENCES:
patent: 5212071 (1993-05-01), Fearon et al.
Takeuchi, M., et al. (1988) J. Biol. Chem. 263: 3657-63.
Parekh, R. B., et al. (1989) Treads Biotechnol F: 117-122.
Mulligan et al., 1992, "Lung Injury After Deposition of IgA Immune Complexes," J. Immunol. 148:3086-3092.
Mulligan et al., 1992, "Protective Effects of Soluble CR1 in Complement and Neutrophil-Mediated Tissue Injury," J. Immunol 148:1479-1485.
Pruitt et al., 1991, "The Effect of Soluble Complement Receptor Type 1 on Hyperacute Xenograft Rejection," Transplantation 52:868-873.
Pruitt and Bolinger, 1991, "The Effects of Soluble Complement Receptor Type 1 on Hyperacute Allograft Rejection," J. Surg. Res. 50:350-355.
Yeh et al., 1991, "Recombinant Soluble Human Complement Receptor Type 1 Inhibits Inflammation In The Reversed Passive Arthus Reaction in Rats," J. Immunol. 146:250-256.
Weisman et al., 1990, "Soluble Human Complement Receptor Type 1: In Vivo Inhibitor of Complement Suppressing Post Ischemic Myocardial Inflammation and Necrosis," Science 249:146-151.
Yoon and Fearon, 1985, "Characterization of a Soluble Form of the C3b/C4b receptor (CR1) In Human Plasma," J. Immunol. 134:3332-3338.
Krych et al., 1989, "A Secreted Small Form of Human Complement C3b/C4b Receptor (CR1) that Binds to C4b But Not C3B," F.A.S.E.B. J. 3:A368.
Klickstein et al., 1988, "Identification of Distinct C3b and C4b Recognition Sites in the Human C3b/C4b Receptor (CR1,CD35) By Deletion Mutagenesis," J. Exp. Med. 168:1699-1717.
Hourcade et al., 1988, "Identification of an Alternative Polyadenylation Site in the Human C3b/C4b Receptor (Complement Receptor Type 1) Transcriptional Unit and Prediction of a Secreted Form of Complement Receptor Type 1," J. Exp. Med. 168:1255-1270.
Klickstein et al., 1987, "Human C3b/C4b Receptor (CR1)," J. Exp. Med. 165:1095-1112.
Wong et al., 1985, "Rapid Purification of the Human C3b/C4b Receptor (CR1) by Monoclonal Antibody Affinity Chromatography," J. Immunol. Methods 82:303-313.
Lublin et al., 1986, "Influence of Glycosylation on Allelic and Cell-specific Mr. Variation, Receptor Processing, and Ligand Binding of the Human Complement C3b/C4b Receptor," J. Biol. Chem. 261:5736.
Sim, 1985, "Large-Scale Isolation of Complement Receptor Type 1 (CR1) From Human Erythrocytes," Biochem J. 232:883-889.
Skubitz and Snook, 1987, "Monoclonal Antibodies That Recognize Lacto-N-Fucopentaose III (CD15) React With the Adhesion-Promoting Glycoprotein Family (LFA-1/HMAC-1/GP 150,95) and CR1 On Human Neutrophils," J. Immunol. 139:1631-1639.
West, 1986, "Current Ideas on the Significance of Protein Glycosylation," Mol. Cell. Biochem. 72:3-20.
Goochee and Monica, 1990, "Environmental Effects on Protein Glycosylation," Bio/Technology 8:421-427.
Freeman Anne M.
Gosselin Michael L.
Lifter John
Marsh, Jr. Henry C.
Smith Richard A. G.
Draper Garnette D.
Fitzgerald David L.
SmithKline Beecham p.l.c.
T Cell Sciences, Inc.
LandOfFree
Glycoform fractions of recombinant soluble complement receptor 1 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Glycoform fractions of recombinant soluble complement receptor 1, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Glycoform fractions of recombinant soluble complement receptor 1 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2309121